HUSCAP logo Hokkaido Univ. logo

Hokkaido University Collection of Scholarly and Academic Papers >
医学研究院・医学院  >
雑誌発表論文等  >

A Comparison of the Effects of the GLP-1 Analogue Liraglutide and Insulin Glargine on Endothelial Function and Metabolic Parameters : A Randomized, Controlled Trial Sapporo Athero-Incretin Study 2 (SAIS2)

この資料はクリエイティブ・コモンズ・ライセンスの下で公開されています。

フルテキスト
fetchObject.pdf433.76 kBPDF見る/開く
この文献へのリンクには次のURLを使用してください:http://hdl.handle.net/2115/59900

タイトル: A Comparison of the Effects of the GLP-1 Analogue Liraglutide and Insulin Glargine on Endothelial Function and Metabolic Parameters : A Randomized, Controlled Trial Sapporo Athero-Incretin Study 2 (SAIS2)
著者: Nomoto, Hiroshi 著作を一覧する
Miyoshi, Hideaki 著作を一覧する
Furumoto, Tomoo 著作を一覧する
Oba, Koji 著作を一覧する
Tsutsui, Hiroyuki 著作を一覧する
Miyoshi, Arina 著作を一覧する
Kondo, Takuma 著作を一覧する
Tsuchida, Kenichi 著作を一覧する
Atsumi, Tatsuya 著作を一覧する
Manda, Naoki 著作を一覧する
Kurihara, Yoshio 著作を一覧する
Aoki, Shin 著作を一覧する
SAIS Study Group 著作を一覧する
発行日: 2015年 8月19日
出版者: PLOS
誌名: PLoS ONE
巻: 10
号: 8
開始ページ: e0135854
出版社 DOI: 10.1371/journal.pone.0135854
抄録: Objectives GLP-1 improves hyperglycemia, and it has been reported to have favorable effects on atherosclerosis. However, it has not been fully elucidated whether GLP-1 is able to improve endothelial function in patients with type 2 diabetes. Therefore, we investigated the efficacy of the GLP-1 analogue, liraglutide on endothelial function and glycemic metabolism compared with insulin glargine therapy. Materials and Methods In this multicenter, prospective randomized parallel-group comparison study, 31 diabetic outpatients (aged 60.3 +/- 10.3 years with HbA1c levels of 8.6 +/- 0.8%) with current metformin and/or sulfonylurea treatment were enrolled and randomly assigned to receive liraglutide or glargine therapy once daily for 14 weeks. Flow mediated dilation (FMD), a comprehensive panel of hemodynamic parameters (Task Force Monitor), and serum metabolic markers were assessed before and after the treatment period. Results A greater reduction (worsening) in % FMD was observed in the glargine group, although this change was not statistically different from the liraglutide group (liraglutide; 5.7 to 5.4%, glargine 6.7 to 5.7%). The augmentation index, C-peptide index, derivatives of reactive oxygen metabolites and BMI were significantly improved in the liraglutide group. Central systolic blood pressure and NT-proBNP also tended to be improved in the liraglutide-treated group, while improvements in HbA1c levels were similar between groups. Cardiac index, blood pressure and most other metabolic parameters were not different. Conclusions Regardless of glycemic improvement, early liraglutide therapy did not affect endothelial function but may provide favorable effects on beta-cell function and cardioprotection in type 2 diabetics without advanced atherosclerosis.
資料タイプ: article
URI: http://hdl.handle.net/2115/59900
出現コレクション:雑誌発表論文等 (Peer-reviewed Journal Articles, etc)

提供者: 三好 秀明

 

本サイトに関するご意見・お問い合わせは repo at lib.hokudai.ac.jp へお願いします。 - 北海道大学